Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I have read that is being done, the injecting of the cells, and they find their way to the eye....it is at the animal level of development, I have read.
"Vitrectomy is often performed with local anesthesia and sedation. You will not be completely asleep during the operation, but you will be very relaxed and feel no pain."
Thanks and Happy New Year.
Hoppalong DD doesn't dig deep enough to connect the dots....Lanza...Advanced Cell Technology...Ocata....a Winner of Discover magazine readers poll for 2014 article of the year....
That article which includes OCAT did win the readers poll!
There is some running going on here....
I love that list....its huge.
It's not that dire....the greater portion of 20 million of Lincoln arrangement is available....and most likely renewable if the case really needed that.
I'm going to let my hair grow!
Merry Christmas and Happy New Year.
Happy Holiday
Ocatas Hemangioblast eMSC are now patent allowable....big news!
looks like you posted your answer after hours, you know what that means.....
"So people can forget." That is your spin. Many investors have been begging for some sort of communication. Well the end of the week came and looks like they decided to try to appease some.
8-k highlights, from a post by Stemdynasty of Icell:
1.They pushed up the timeline to share interim data by 3 quarters.
2.They moved MMD back and AMD ahead. Nothing they can be better than moving AMD ahead a full quarter to April.
3.The fact that they pushed up AMD an entire quarter is worth several dollars to the share price.
4.Another positive is they readjusted the number of patients in the study, and that number of patients was decreased. This can only be attributed to something the FDA RECENTLY saw. This change will allow us to move thru the trials much quicker.
As some lighten, others eagerly load up.
8-k highlights, from a post by Stemdynasty of Icell:
1.They pushed up the timeline to share interim data by 3 quarters.
2.They moved MMD back and AMD ahead. Nothing they can be better than moving AMD ahead a full quarter to April.
3.The fact that they pushed up AMD an entire quarter is worth several dollars to the share price.
4.Another positive is they readjusted the number of patients in the study, and that number of patients was decreased. This can only be attributed to something the FDA RECENTLY saw. This change will allow us to move thru the trials much quicker.
Well, that is not anything to do with OCAT.
8-k highlights, from a post by Stemdynasty of Icell:
1.They pushed up the timeline to share interim data by 3 quarters.
2.They moved MMD back and AMD ahead. Nothing they can be better than moving AMD ahead a full quarter to April.
3.The fact that they pushed up AMD an entire quarter is worth several dollars to the share price.
4.Another positive is they readjusted the number of patients in the study, and that number of patients was decreased. This can only be attributed to something the FDA RECENTLY saw. This change will allow us to move thru the trials much quicker.
If there is good news regarding Jordan....think over $4 pps.
Not entirely true. There are/is another way to uplist before 90 days. I'm sure you know that.
"12/18/14, that's today's date last time I checked. So, OTC IT IS and "NASDAQ POSTPONED" it is. That's the final word from FINRA."
You probably mean that is the latest word from FINRA. Final word implies there will be no change ever.
Intriguing
Some facts with a negative spin.
I think it is worth noting that when we see an article that says they "injected stem cells into the eye," the more accurate term should be RPE cells. One of the main reasons (IMO) Advanced Cell Technology changed their name to Ocata Therapeutics was to differentiate themselves from stem cell companies to what they think of themselves as, a tissue regenerative company. The Stem cells are terminally differentiated, and that is significantly different from those reckless companies that tout the injection of raw stem cells (which could change into something quite different than you would want).
volume at 161 k right now....retail is not locked out.
Check....Nasdaq listed on my account as well....check
That is what I saw, as well.
I don't think companies on the Nasdaq clamor to get to the OTC. Also, if officers of the company of a start up biotech "bought" shares on the open market, it would probably be viewed as market manipulation.
As part of the Termination Plan (as defined and described below), the Company plans to terminate the employment of Mr. Miclot, Mr. Davis and Dr. Bertram effective December 5, 2014, December 23, 2014 and December 5, 2014, respectively.
On December 1, 2014, the Company’s Board of Directors (the “Board”) approved a plan of termination (the “Termination Plan”) that will result in a workforce reduction of all of the Company’s 29 employees (the “Terminated Employees”), including Mr. Miclot, Mr. Davis and Dr. Bertram, by the end of 2014. The Terminated Employees serve in research, development, financial and administrative roles.
This one has been bouncing around some pretty large percentages as of late.
It lists Gary Rabin as CEO.....????
Something must be up.........
I did find this though....http://www.marketwatch.com/investing/stock/ocat
Whoa Nellie up 50% today!
I concur. Also, would it be reasonable to expect 20/20 vision when possible restoration could be 20/40 for such individuals. Let's say they get to 20/40, could be with Lasik they make it to 20/20, as perfect sight depends on more than just the photoreceptors...rpe etc. functioning. Just a thought.
yeah, the bionic solution probably requires batteries....that eventually would leak....acid....think of the horror.
It would be fair to say that it is incubating. The partnering of the platelet program will bring much capital to the plate and change the complexion of the pps concerns.
Volume 500,000 above average today. Is something up?
Yeah, Langer is more than just a name on the board here at Ocat, In a recent publication Dr. Lanza mentions his contributions....recall something along the lines of "microfliudics" any one else with details?
Some posted a MM's own words about price movement. Basically when the price is up they are going to short the stock...in absence of news they then step the price down and induce others to sell so they can cover the short. Some say this is less likely to happen on the nasdaq. Well, lets hope so.
The other way in which nasdaq uplist happens if there is 5 million dollars in shareholder equity. At any point this happens, uplist is possible. Other than that, the 90 days....